CN103717571A - 9-氨基甲基取代的四环素类化合物 - Google Patents
9-氨基甲基取代的四环素类化合物 Download PDFInfo
- Publication number
- CN103717571A CN103717571A CN201280037036.6A CN201280037036A CN103717571A CN 103717571 A CN103717571 A CN 103717571A CN 201280037036 A CN201280037036 A CN 201280037036A CN 103717571 A CN103717571 A CN 103717571A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- bases
- base
- yue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Abstract
Description
Claims (1)
- 权 利 要 求1. 通式( I )所示的化合物、 其药学上可接受的盐、 其前体药物. 其溶剂化物或其异构体:其中,R2a、 R2b、 R3、 R1G、 R11和 R12分别独立地为氢;R5、 R6a、 R6b和 R8分别独立地为: 氢、 巯基、 卤素、 羟基、 氨基、 羧基、 d.6烷基、 卤代 d-6烷基、 C2-6烯基、 C2-6炔基、 d-6烷氧基、 卤 代 CM烷氧基、 d.6烷硫基、 烷基胺基、 二 (C1 -6烷基)胺基、 羟基 坑基、 羧基 d.6烷基、 氨基 d_6烷基、 d.6烷基胺基(^.6烷基、 d.6 烷基欺基、 d-6烷基羰氧基、 烷氧基羰基、 烷基亚磺酰基、 d_6 烷基磺酰基、 磺酸基、 磺酰基 烷基、 磺酰胺基、 磺酖胺基 C1-6烷 基、 烷基磺酰胺基、 氨基磺酰基、 d.6烷基胺基磺酰基、 二 (d-6烷 基)胺基磺酰基、 氨基磺酰基 d.6烷基、 d.6烷基曱酰胺基、 d.6烷基胺 基甲酰基、 二 (Cw烷基)胺基甲酰基、 氨基甲酰基、 氨基甲酰基 d_6烷 基、 3卜 8元环烷基、 6-14元芳基、 6-14元芳基 C1-6烷基、 6-14元芳基曱 酰基、 6-14元芳基曱酰氧基、 3-8元杂环基、 3-8元杂环基 d-6烷基、 6-14元杂芳基或 6-14元杂芳基 烷基;R7为: NR7aR7b;R4a、 R4b、 R7a和 R7b分别独立地为: 氢、 d.6烷基、 卤代 d.6烷基、 C2-6烯基、 C2.6炔基、 d_6烷氧基、 卤代 C1-6烷氧基、 C1-6烷硫基、 羟基 烷基、 羧基 d.6烷基、 氨基 d.6烷基、 d.6烷基胺基(^.6烷基、 C1-6 烷基羰基、 烷氧基羰基、 烷基亚磺酰基、 d.6烷基磺酰基、 磺 酸基、 磺酰基 烷基、 磺酰胺基 d_6烷基、 氨基磺酰基、 C1-6烷基胺 基磺酰基、 二 (C1-6烷基)胺基磺酰基、 氨基磺酰基 d.6烷基、 d.6烷基 胺基甲酰基、 二 (C1 -6烷基)胺基曱酰基、 氨基曱酰基、 氨基甲酰基 C1-6 烷基、 3-8元环烷基、 6-14元芳基、 6- 14元芳基、 6-14元芳基 C1-6烷基、 3-14无杂环基或 3-14元杂环基 C^6烷基;R!9a、 R9b分别独立地为:( 1 ) 氢, 且 R9a、 R9b不能同时为氢,( 2 )未被取代或被 1-3个相同或不同的 Q1取代的: 环丙烷基、 环 丁烷碁、 6-12元螺环基、 6元桥环基、 8-12元桥环基或 6-10元饱和稠 环基,且所述的环丙烷基、环丁烷基、 6-12元螺环基、 6元桥环基、 8-12 元桥坏基和 6-10元饱和稠环基中的碳原子可以被 1-3个相同或不同的 0、 CO、 S、 SO、 S02、 N或 NRe替换, R。代表氢或 d.6烷基;( 3 )未被取代或被 1-3个相同或不同的 Q1取代的: 环丁烷基。1-6 烷基、 环戊烷基 d_6烷基、 6-12元螺环基 d_6烷基、 6-9元桥环基 C1-6 烷基或 6-10元饱和稠环基 C1-6烷基, 且所述的环丁烷基、 6-12元螺环 基和 6-9元桥环基中的碳原子可以被 1-3个相同或不同的 0、 CO、 S、 SO、 S02、 N或 NRe替换, 所述的 6-10元饱和稠环基中的碳原子可以 被 1-3个相同或不同的 CO、 S、 SO、 S02、 N或 NRe替换, R°代表氢 或 Ci-6烷基;或 R9a、 R9b与所连接的 N原子一起形成未被取代或被 1-3个相同 或不同的 Q2取代的氮杂环丁烷基、 6-9元螺环基或 6-9元饱和稠环基, 且所述的氮杂环丁烷基、 6-9元螺环基和 6-9元饱和稠环基中的碳原子 可以被 1-3个相同或不同的 0、 CO、 S、 SO、 S02、 N或 NRe替换, Rc 代表氢或 d-6烷基;Q\ Q2分别独立地选自卤素、 羟基、 氨基、 羧基、 c1-6烷基、 c1-6 烷氧基、 代 C1-6烷基、 代( 1-6烷氧基、 羟基 c1-6烷基、 氨基 c1-6 烷基、 羧基 d_6烷基、 C1-6烷基胺基、 二 (C1-6烷基)胺基、 氨基磺酰基、 氨基璜酰基 C1-6烷基、 氨基曱酰基、 氨基曱酰基 C1-6烷基、 d-6烷基羰 基、 烷基羰氧基、 C1-6烷氧基羰基、 苯基、 3-8元环烷基或 3-8元杂 环基;R13a、 R13b分别独立地为: 氢、 C1-6烷基或 3-8元环烷基。2. 权利要求 1所迷的化合物、 其药学上可接受的盐、 溶剂化物或 其异构体, 其中通式(I ) 具有下 ^通式 (II ) 所示的结构:R9a、 R9B分别如权利要求 1中所定义。3. 权利要求 1所述的化合物、 其药学上可接受的盐、 溶剂化物或 其异构体, 其中通式 (I )具有下述通式(ΙΠ ) 所示的结构:其中, R9A、 R9B分别如权利要求 1中所定义。4. 如权利要求 3所述的化合物、 其药学上可接受的盐、 其前体药 物、 其溶剂化物或其异构体:其中,R9A、 R9B分别独立地为:( 1 ) 氢, 且 R9A、 R9B不能同时为氢,( 2 )未被取代或被 1-3个相同或不同的 Q1取代的环丙烷基、环丁 烷基、 6-10元螺环基、 6元桥环基或 6-10元饱和稠环基, 且所述的环 丙烷基、 环丁烷基、 6-10元螺环基、 6元桥环基和 6-10元饱和稠环基 中的碳原子可以被 1-3个相同或不同的 0、 CO、 N或 NR°替换, RE代 表氢或 CM烷基,( 3 ) 未被取代或被 1-3 个相同或不同的 Q1取代的环丁烷基 C1-4 烷基、 环戊烷基 CM烷基、 6-10元螺环基 C1-4烷基、 6-9元桥环基(^-4 烷基或 6-10元饱和稠环基 d-4烷基, 且所述的环丁烷基、 6-10元螺环 基和 6-9元桥环基中的碳原子可以被 1-3个相同或不同的 0、 CO、 N 或 NRC替换, 所述的 6-10元饱和稠环基中的碳原子可以被 1-3个相同 或不同的 CO、 N或 NRE替换, RE代表氢或( μ4烷基;或 R9A、 R9B与所连接的 N原子一起形成未被取代或被 1-3个相同或不 同的 (^取代的氮杂环丁烷基、 6-9元螺环基或 6-9元饱和稠环基, 且所述 的氮杂环丁烷基、 6-9元螺环基和 6-9元饱和稠环基中的碳原子可以被 1-3个相同或不同的 0、 CO、 N或 NRe替换, Re代表氢或(^-4烷基;qK Q2分别独立地选自卤素、 羟基、 氨基、 羧基、 CM烷基、 CM 烷氧基或! ¾代(^.4烷基。5. 如权利要求 4所述的化合物、 其药学上可接受的盐、 其前体药 物、 其溶剂化物或其异构体:其中,R9a、 R9b分别独立地为:( 1 ) 氢, 且 R9a、 R9b不能同时为氢,( 2 )未被取代或被 1 -3个相同或不同的 Q1取代的环丙烷基、环丁烷 基、 6;-8元螺环基或 6元桥环基, 且所述的环丙烷基、 环丁烷基、 6-8元 螺环基和 6元桥环基中的碳原子可以被 1 -3个相同或不同的 0、 N或 NRe 替换, Re代表氢、 曱基或乙基;( 3 ) 未被取代或被 1 -3个相同或不同的 Q1取代的环丁烷基 C1-3烷 基、 环戊烷基(^.3烷基、 6-8元螺环基 d_3烷基、 6-8元桥环基(^-3烷基, 且所迷的环丁烷基、 6-8元螺环基和 6-8元桥环基中的碳原子可以被 1-3 个相! ¾或不同的 0、 N或 NIT替换, Re代表氢、 甲基或乙基;或 R9a、 R9b与所连接的 N原子一起形成未被取代或被 1-3个相同 或不 [¾的 Q2取代的氮杂环丁烷基、 6-8元螺环基或 6-9元饱和稠环基, 且所迷的氮杂环丁烷基、 6-8元螺环基和 6-9元饱和稠环基中的碳原子 可以被 1-3个相同或不同的 0、 N或 NRC替换, Rc代表氢、 曱基或乙 基;Q\ Q2分别独立地选自 素、 d.4烷基或氨基。6. 如权利要求 5所述的化合物、 其药学上可接受的盐、 其前体药 物、 其溶剂化物或其异构体:其中,U9\ R9b分别独立地为:( 1 ) 氢, 且 R9a、 R9b不能同时为氢,( 2 ) 未被取代或被 1-3 个相同或不同的 Q1取代的 ^、 ^° (3)未被取代或被 1-3个相同或不同的 Q1 .、^X>、 、^X、/J A^;或 R9a、 R9b与所连接的 N原子一起形成未被取代或被 1-3个相同或不同的 Q2取代的 ^、、Q1, Q2分别独立地选自氟原子、 氯原子、 曱基或氨基。7. 如权利要求 1所述的化合物、 其药学上可接受的盐、 其前体药 物、t9100100/1101^3/ I d sosno/fioz: OAV8. 药物组合物, 该组合物包含权利要求 1 所述的化合物、 其药学 上可接受的盐、 其前体药物、 其溶剂化物或其异构体、 以及药用载体 和 /或稀释剂。9. 如权利要求 1所述的化合物、 其药学上可接受的盐、 其前体药 的疾病的药物中的应用, 所述对四环素类药物敏感的疾病例如是感染、 它疾病。10. 一种制备通式 (I ) 所示的化合物、 其药学上可接受的盐、 其 前体药物、 其溶剂化物或其异构体的方法, 该方法包括使原料 1 化合 物与 N-碘代丁二酰亚胺反应得到中间体 1化合物, 中间体 1在催化剂 的作用下反应得到中间体 2化合物, 然后使中间体 2化合物与原料 2 化合物反应, 得到通式 (I ) 所示的化合物、 其药学上可接受的盐、 其 前体药物、 其溶剂化物或其异构体:式 (I)其中 R2a、 R2b、 R3、 R4a、 R4b、 R5、 R6a、 R6b、 R'、 Rs、 R 、 R R10、 Ru、 R12如权利要求 1中所定义。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280037036.6A CN103717571B8 (zh) | 2011-07-26 | 2012-07-26 | 9‑氨基甲基取代的四环素类化合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110222016.3 | 2011-07-26 | ||
CN201110222016 | 2011-07-26 | ||
CN201280037036.6A CN103717571B8 (zh) | 2011-07-26 | 2012-07-26 | 9‑氨基甲基取代的四环素类化合物 |
PCT/CN2012/001001 WO2013013505A1 (zh) | 2011-07-26 | 2012-07-26 | 9-氨基甲基取代的四环素类化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN103717571A true CN103717571A (zh) | 2014-04-09 |
CN103717571B CN103717571B (zh) | 2016-01-13 |
CN103717571B8 CN103717571B8 (zh) | 2017-05-17 |
Family
ID=47600513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280037036.6A Active CN103717571B8 (zh) | 2011-07-26 | 2012-07-26 | 9‑氨基甲基取代的四环素类化合物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9365499B2 (zh) |
EP (1) | EP2738156B1 (zh) |
JP (1) | JP5792902B2 (zh) |
KR (1) | KR101732084B1 (zh) |
CN (1) | CN103717571B8 (zh) |
BR (1) | BR112014001798B1 (zh) |
CA (1) | CA2842838C (zh) |
DK (1) | DK2738156T3 (zh) |
ES (1) | ES2664516T3 (zh) |
HK (1) | HK1191931A1 (zh) |
HR (1) | HRP20180444T1 (zh) |
HU (1) | HUE036696T2 (zh) |
LT (1) | LT2738156T (zh) |
NO (1) | NO2738156T3 (zh) |
PL (1) | PL2738156T3 (zh) |
PT (1) | PT2738156T (zh) |
SI (1) | SI2738156T1 (zh) |
WO (1) | WO2013013505A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106883138A (zh) * | 2017-03-01 | 2017-06-23 | 郑州大学第附属医院 | 老虎素的制备方法 |
TWI656116B (zh) * | 2016-06-22 | 2019-04-11 | 山東亨利醫藥科技有限責任公司 | Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
PT2738156T (pt) | 2011-07-26 | 2018-03-28 | Kbp Biosciences Usa Inc | Compostos de tetraciclina substituídos por 9-aminometil |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN103073481A (zh) * | 2013-02-06 | 2013-05-01 | 上海药明康德新药开发有限公司 | 一种4-氮杂螺[2.4]庚烷盐酸盐的制备方法 |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN105384673B (zh) * | 2015-11-09 | 2017-11-14 | 南京富润凯德生物医药有限公司 | 3‑氟代‑氮杂环丁烷衍生物的合成方法 |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CA3095102A1 (en) * | 2018-04-06 | 2019-10-10 | Paratek Pharmaceuticals, Inc. | Process for making sarecycline hydrochloride |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
CN1649582A (zh) * | 2002-03-08 | 2005-08-03 | 帕拉特克药品公司 | 氨基-甲基取代的四环素类化合物 |
CN101759604A (zh) * | 2008-09-12 | 2010-06-30 | 山东轩竹医药科技有限公司 | 胍基取代的四环素衍生物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03000055A (es) | 2000-07-07 | 2003-07-14 | Tufts College | Compuestos de monociclina sustituidos en posicion 9.. |
US20030012352A1 (en) * | 2001-07-13 | 2003-01-16 | Serdar Kiykioglu | Application of metering tones to a DSL and voice communications network |
AU2003287218C1 (en) * | 2002-10-24 | 2010-07-15 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
AU2004259659B2 (en) * | 2003-07-09 | 2011-11-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
SI2109602T1 (sl) * | 2006-12-21 | 2014-06-30 | Paratek Pharmaceuticals, Inc. | Derivati tetraciklina za zdravljenje bakterijskih, virusnih in parazitskih infekcij |
PT2738156T (pt) | 2011-07-26 | 2018-03-28 | Kbp Biosciences Usa Inc | Compostos de tetraciclina substituídos por 9-aminometil |
-
2012
- 2012-07-26 PT PT128177748T patent/PT2738156T/pt unknown
- 2012-07-26 EP EP12817774.8A patent/EP2738156B1/en active Active
- 2012-07-26 DK DK12817774.8T patent/DK2738156T3/en active
- 2012-07-26 CA CA2842838A patent/CA2842838C/en active Active
- 2012-07-26 LT LTEP12817774.8T patent/LT2738156T/lt unknown
- 2012-07-26 KR KR1020147005035A patent/KR101732084B1/ko active IP Right Grant
- 2012-07-26 SI SI201231256T patent/SI2738156T1/en unknown
- 2012-07-26 JP JP2014521914A patent/JP5792902B2/ja active Active
- 2012-07-26 ES ES12817774.8T patent/ES2664516T3/es active Active
- 2012-07-26 BR BR112014001798-0A patent/BR112014001798B1/pt active IP Right Grant
- 2012-07-26 WO PCT/CN2012/001001 patent/WO2013013505A1/zh active Application Filing
- 2012-07-26 NO NO12817774A patent/NO2738156T3/no unknown
- 2012-07-26 PL PL12817774T patent/PL2738156T3/pl unknown
- 2012-07-26 HU HUE12817774A patent/HUE036696T2/hu unknown
- 2012-07-26 CN CN201280037036.6A patent/CN103717571B8/zh active Active
- 2012-07-26 US US14/234,420 patent/US9365499B2/en active Active
-
2014
- 2014-06-06 HK HK14105301.7A patent/HK1191931A1/zh unknown
-
2018
- 2018-03-15 HR HRP20180444TT patent/HRP20180444T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1649582A (zh) * | 2002-03-08 | 2005-08-03 | 帕拉特克药品公司 | 氨基-甲基取代的四环素类化合物 |
WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
CN101759604A (zh) * | 2008-09-12 | 2010-06-30 | 山东轩竹医药科技有限公司 | 胍基取代的四环素衍生物 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI656116B (zh) * | 2016-06-22 | 2019-04-11 | 山東亨利醫藥科技有限責任公司 | Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof |
US10633337B2 (en) | 2016-06-22 | 2020-04-28 | Kbp Biosciences Co., Ltd. | Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof |
CN106883138A (zh) * | 2017-03-01 | 2017-06-23 | 郑州大学第附属医院 | 老虎素的制备方法 |
CN106883138B (zh) * | 2017-03-01 | 2018-07-10 | 郑州大学第一附属医院 | 老虎素的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
PL2738156T3 (pl) | 2018-06-29 |
DK2738156T3 (en) | 2018-03-26 |
EP2738156A4 (en) | 2015-01-07 |
HK1191931A1 (zh) | 2014-08-08 |
CN103717571B8 (zh) | 2017-05-17 |
PT2738156T (pt) | 2018-03-28 |
JP5792902B2 (ja) | 2015-10-14 |
WO2013013505A1 (zh) | 2013-01-31 |
HRP20180444T1 (hr) | 2018-05-04 |
NO2738156T3 (zh) | 2018-06-02 |
KR101732084B1 (ko) | 2017-05-02 |
CN103717571B (zh) | 2016-01-13 |
KR20140050694A (ko) | 2014-04-29 |
CA2842838A1 (en) | 2013-01-31 |
ES2664516T3 (es) | 2018-04-19 |
EP2738156A1 (en) | 2014-06-04 |
HUE036696T2 (hu) | 2018-07-30 |
JP2014529342A (ja) | 2014-11-06 |
SI2738156T1 (en) | 2018-05-31 |
US20140179638A1 (en) | 2014-06-26 |
CA2842838C (en) | 2017-04-25 |
LT2738156T (lt) | 2018-05-25 |
EP2738156B1 (en) | 2018-01-03 |
US9365499B2 (en) | 2016-06-14 |
BR112014001798B1 (pt) | 2021-07-27 |
BR112014001798A2 (pt) | 2017-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103717571A (zh) | 9-氨基甲基取代的四环素类化合物 | |
CN103635456B (zh) | 替加环素衍生物 | |
EP0708642B1 (en) | Taxol derivatives | |
CA3021061C (en) | Derivatives of amphotericin b | |
CN109776510A (zh) | 一种n-取代咪唑甲酸酯类衍生物及其用途 | |
EP1328527B1 (en) | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | |
TW200940083A (en) | Novel semi-synthetic glycopeptides as antibacterial agents | |
CN111440112B (zh) | 一种热解型二萜生物碱化合物及其制备方法和用途 | |
JP2019521079A (ja) | バンコマイシン誘導体、その製造方法、医薬組成物及び用途 | |
CN111217749A (zh) | 氘代喷他佐辛及制备方法、医药组合物和用途 | |
JPH0977791A (ja) | ペプチド誘導体及びその用途 | |
EP4178574A2 (en) | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer | |
CN113402370A (zh) | 一种二萜衍生物及其制备方法、药物组合物和应用 | |
CN106478570A (zh) | 二甲基胺4-o-乙酰基线叶旋覆花内酯a或其盐及其制备与应用 | |
CN110938114B (zh) | 一类万古霉素硫鎓衍生物、其制备方法、药物组合物和用途 | |
CN112457366B (zh) | 作为蛋白降解剂的并环类化合物及其制备方法和应用 | |
CN108929253B (zh) | 一种截短侧耳素类化合物及其制备方法和应用 | |
CN112778393B (zh) | 欧夹竹桃苷衍生物及其制备方法、药物组合物和用途 | |
WO2018233670A1 (zh) | 苯并异噁唑螺嘧啶三酮类化合物及制备方法和用途 | |
CN117427176A (zh) | 一种药物偶联物及其应用 | |
CN101759598B (zh) | 具有氨基烷基脒的四环素化合物 | |
CN107759503A (zh) | 一种四环素衍生物及其用途 | |
JP2021510732A (ja) | グリコシルトランスフェラーゼ阻害剤 | |
CN101861309A (zh) | Salarin和tulearin以及它们的组合物和应用 | |
CN101684080A (zh) | 含有甲酰肼基的四环素化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1191931 Country of ref document: HK |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application | ||
CI01 | Publication of corrected invention patent application |
Correction item: National priority Correct: 201110222016.3 2011.07.26 CN Number: 02 Volume: 32 |
|
CI03 | Correction of invention patent | ||
CI03 | Correction of invention patent |
Correction item: National priority Correct: 201110222016.3 2011.07.26 CN Number: 02 Page: The title page Volume: 32 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1191931 Country of ref document: HK |